csf1r in 2

CSF1R-IN-2 is an oral-active SRC, MET and c-FMS inhibitor (IC50s: 0.12 nM, 0.14 nM and 0.76 nM for SRC, MET and c-FMS respectively).

Axl/Mer/CSF1R-IN-2 (Comp 4) serves as an inhibitor for Axl, Mer, and CSF1R [1].

PLX5622 hemifumarate is a highly selective, blood-brain barrier-permeable, and orally active CSF1R inhibitor with an IC50 of 0.016 μM and a Ki of 5.9 nM. It can be used to eliminate proliferating and specific microglia before and during disease progression and is applicable for inducing Alzheimer's disease models.

Sulfatinib (KDR-IN-1) (HMPL-012) is a potent and highly selective tyrosine kinase inhibitor against VEGFR1/2/3, FGFR1 and CSF1R with IC 50 s ranging from 1 to 24 nM.

Cabiralizumab (FPA 008) is an anti-CSF1R monoclonal antibody (mAb) that enhances T cell infiltration and strengthens antitumor immune responses. Cabiralizumab prevents osteoclast activation, thereby inhibiting bone destruction, and is employed in rheumatoid arthritis (RA) research. Additionally, Cabiralizumab has been investigated in combination with Nivolumab in lung cancer studies, highlighting its role in immune-oncology.